AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 APR 17 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Alphavirus vectors may be useful for developing vaccines against Lassa and Ebola virus infections, researchers in the United States report.
"Lassa and Ebola viruses cause acute, often fatal, hemorrhagic fever diseases, for which no effective vaccines are currently available," explained Peter Pushko and colleagues with the United States Army Medical Research Institute for Infectious Diseases at Fort Detrick in Frederick, Maryland. "Although lethal human disease outbreaks have been confined so far to sub-Saharan Africa, they also pose significant epidemiological concern worldwide as demonstrated by several instances of accidental importation of the viruses into North America and Europe."
Bivalent vaccines using modified alphavirus replicons protected animals from infection with both Lassa and Ebola virus, Pushko and coworkers found.
The researchers developed a vaccine vector based on recombinant replicon RNA, derived from a form of the virus responsible for Venezuelan equine encephalitis. This RNA was modified to express glycoprotein genes from either Lassa or Ebola virus alone, or from both viruses, they said.
Guinea pigs inoculated with recombinant RNA bound into virus-like replicon particles survived what would have been lethal exposures to Lassa and Ebola viruses, study data showed. The bivalent vaccine ...